How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Specimen Validity Test (SVT) Service Market
- By Test Type: Urine Adulteration Testing, Urine Dilution Testing, Urine Substitution Testing, Urine Temperature Testing, Urine pH Testing
- By End User: Clinical Laboratories, Forensic Laboratories, Workplace Drug Testing Facilities, Rehabilitation Centers, Law Enforcement Agencies
- By Sample Type: Urine Samples, Oral Fluid Samples, Hair Samples, Blood Samples
- By Technology: Immunoassay-Based Testing, Chromatography Techniques, Spectrometry Techniques, Enzymatic Assays
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urine Adulteration Testing leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Specimen Validity Test (SVT) Service Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
End User 5
Sample Type 4
Technology 4
Companies profiled
Quest Diagnostics
LabCorp
Abbott Laboratories
Alere Inc. (now part of Abbott)
Thermo Fisher Scientific
Bio-Rad Laboratories
OraSure Technologies
Phamatech Inc.
Sinochips Bioscience
NMS Labs
MedTox Laboratories
DrugScan Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Quest Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →LabCorp
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Alere Inc. (now part of Abbott)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →OraSure Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Phamatech Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sinochips Bioscience
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →NMS Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MedTox Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →DrugScan Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Redwood Toxicology Laboratory
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Clinical Reference Laboratory
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Aegis Sciences Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,539M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urine Adulteration Testing56.1
- Urine Dilution Testing6.7
- Urine Substitution Testing8.4
- Urine Temperature Testing13.1
- Urine pH Testing15.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,462M → $3,139M · 10.0%
Europe$1,019M → $2,660M · 12.7%
Asia Pacific$930.2M → $2,474M · 13.0%
Latin America$575.8M → $1,283M · 10.5%
Middle East and Africa$442.9M → $1,090M · 11.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.392026
11.412027
11.432028
11.432029
11.452030
11.452031
11.472032
11.492033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Quest Diagnostics18.0
- LabCorp23.6
- Abbott Laboratories6.2
- Alere Inc. (now part of Abbott)6.6
- Thermo Fisher Scientific12.1
- Bio-Rad Laboratories5.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type31.8%
End User17.6%
Sample Type22.1%
Technology28.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.5
- Europe25.0
- Asia Pacific23.2
- Latin America12.1
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Quest Diagnostics | 76 | 88 | 76 | 79 | 73 | 84 | 79 |
| LabCorp | 73 | 89 | 77 | 71 | 74 | 69 | 76 |
| Abbott Laboratories | 66 | 80 | 67 | 87 | 83 | 74 | 76 |
| Alere Inc. (now part of Abbott) | 59 | 73 | 76 | 70 | 81 | 63 | 70 |
| Thermo Fisher Scientific | 73 | 66 | 61 | 71 | 66 | 64 | 67 |
| Bio-Rad Laboratories | 64 | 51 | 71 | 46 | 62 | 49 | 57 |
| OraSure Technologies | 49 | 44 | 65 | 57 | 48 | 48 | 52 |
| Phamatech Inc. | 51 | 45 | 55 | 50 | 48 | 41 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Quest Diagnostics
- LabCorp
- Abbott Laboratories
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Quest Diagnostics | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| LabCorp | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Abbott Laboratories | ◐ | ✓ | − | ✓ | ◐ | ◐ |
| Alere Inc. (now part of Abbott) | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Thermo Fisher Scientific | ✓ | − | ◐ | − | ✓ | ✓ |
| Bio-Rad Laboratories | − | − | − | − | ✓ | − |
| OraSure Technologies | − | − | − | ◐ | − | − |
| Phamatech Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Quest Diagnostics79
2LabCorp76
3Abbott Laboratories76
4Alere Inc. (now part of Abbott)70
5Thermo Fisher Scientific67
6Bio-Rad Laboratories57
7OraSure Technologies52
8Phamatech Inc.48
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Quest Diagnostics
Challenger4
Strong scale, closing on the leaders.
LabCorpAbbott LaboratoriesAlere Inc. (now part of Abbott)Thermo Fisher Scientific
Contender1
Focused players with pockets of strength.
Bio-Rad Laboratories
Niche2
Specialists in a single segment or region.
OraSure TechnologiesPhamatech Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Specimen Validity Test (SVT) Service Market — a $227M beachhead inside a $3.07B market.
Beachhead (SOM)$227Mobtainable near-term
Serviceable (SAM)$1.27Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Urine Adulteration Testing
Best fit — highest urgency & budget in Test Type.
Economic buyer77 fit
Urine Dilution Testing
Strong fit — clear ROI and a fast path to value.
End user68 fit
Urine Substitution Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve23%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Specimen Validity Test (SVT) Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation12%
Closed-won6%
$19.7KCAC
$101KLTV
5.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Specimen Validity Test (SVT) Service Market is a durable-growth opportunity — $7.75B by 2033, compounding at 9.5%.
TAM · 2025$3.76Btoday
TAM · 2033$7.75Bforecast
CAGR9.5%2027–2033
Cumulative$49.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.75BTotal addressable market
SAM$3.24BServiceable available market
SOM$641MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.75BLarge & growingTAM by 2033 at 9.5% CAGR
$3.24BServiceable nowreachable with today’s model
$641MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.04BBear6.1% CAGR
$7.75BBase9.5% CAGR
$9.92BBull12.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Specimen Validity Test (SVT) Service Market — a $7.15B market by 2033. Plan: grow share from 6.7% to 12.3%.
Market size · 2033$7.15Btotal addressable
Market CAGR3.9%2027–2033
Target share12.3%from 6.7% today
Revenue ambition$880Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 12.3% | Behind |
| Revenue | $480M | $880M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 30.1% | 45.7% | On track |
| Customer retention | 90.2% | 92.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Specimen Validity Test (SVT) Service Market conversation — a $10.1B market you can size, segment and defend in minutes.
Market size · 2033$10.1Btotal opportunity
Growth9.5%CAGR to 2033
Addressable buyers1,394+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 3 mopayback period
$92K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Quest DiagnosticsLabCorpAbbott LaboratoriesAlere Inc. (now part of Abbott)Thermo Fisher ScientificBio-Rad LaboratoriesOraSure TechnologiesPhamatech Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Specimen Validity Test (SVT) Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Specimen Validity Test (SVT) Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Specimen Validity Testing Products Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportSpecimen Validity Testing Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportSpecimen Transport Box Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportSpecimen Retrieval Bag Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportSpecimen Processing Equipment Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportSpecimen Processing Device Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportSpecimen Preparation Equipment Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportSpecimen Collection Swab Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportSpecimen Collection Kit Market
Market size, share, segmentation and regional forecast.
$789M market · 2025 base year
View reportSpecimen Collection Device Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSpecimen Collection Card Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportSpecific Protein Testing Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.